This page is updated frequently with new Gly-related patent applications. Subscribe to the Gly RSS feed to automatically get the update: related Gly RSS feeds. RSS updates for this page: Gly RSS
Systems for treating pulmonary infections
|| List of recent Gly-related patents
| Assay for analyses of rabies virus glycoprotein|
Provided are processes of determining die immimogenicity of a rabies virus vaccine preparation that for the first tiine correlates well with in vivo results. The methods capitalize on an ecl assay for rabv g protein that is sensitive, reproducible, and can be used to quickly assess characteristics of new vaccine preparations..
The Usa, As Represented By The Secretary, Dept. Of Health & Human Service,centers For Disease Contro
| Salivary protein glycosylation test for diagnosis and monitoring of diabetes|
Disclosed herein are methods and tests for diagnosing and/or monitoring a metabolic condition such as diabetes in a subject, wherein the methods and tests measure salivary glycoproteins. Some of the methods are based on the oxidation of glycoproteins in a sample from the subject, such as saliva or urine, for example using sodium metaperiodate, and then detecting the aldehydes generated during oxidation using a chemical detection method.
| Method to identify disease resistant quantitative trait loci in soybean and compositions thereof|
The present invention is in the field of plant breeding and genetics, particularly as it pertains to the genus, glycine. More specifically, the invention relates to a method for screening soybean plants containing one or more quantitative trait loci for disease resistance, species of glycine having such loci and methods for breeding for and screening of glycine with such loci.
Monsanto Technology Llc
| Method of identifying or evaluating beneficial actives and compositions containing the same|
A method of identifying or evaluating skin-care actives that improve the metabolism of a skin cell. The method includes contacting cells with a stressor and a test agent and determining a response of the cells to the stressor and test agent, based on the change in metabolic indicators associated with glycolysis and/or oxidative phosphylation.
The Procter & Gamble Company
| Thermophilic and thermoacidophilic biopolymer degrading genes and enzymes from alicyclobacillus acidocaldarius and related organisms, methods|
Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from alicyclobacillus acidocaldarius are provided. Further provided are methods of at least partially degrading, cleaving, or removing polysaccharides, lignocellulose, cellulose, hemicellulose, lignin, starch, chitin, polyhydroxybutyrate, heteroxylans, glycosides, xylan-, glucan-, galactan-, or mannan-decorating groups using isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from alicyclobacillus acidocaldarius..
Battelle Energy Alliance, Llc
| Dissolvable aqueous gels with high chelant loading|
Described are aqueous gel compositions for forming a chelant gel, comprising from 4 wt. % to 60 wt.
Dow Global Technologies Llc
| Solid soap|
[means of solving] a solid soap comprising 20 to 70 mass % of fatty acid soaps, wherein the solid soap comprises dimethyldiallylammonium chloride/acrylamide polymer and a high-molecular polyethylene glycol.. .
| Lauric ester compositions|
Provided are compositions containing alkyl esters derived from triglyceride oils produced from genetically engineered microalgae. Specific embodiments relate to esters derived from oils with high c10-c12 fatty acid profile.
| Green glycine betaine derivative compounds and compositions containing same|
Multifunctional green and antimicrobial compositions are described containing cationic glycine betaine esters and/or cationic glycine betaine amides. Particular glycine betaine esters and amides are alkyl(ene) betainate methane sulfonates and betainyl amino alkyl(ene) methane sulfonates.
| Lubricant composition|
A lubricant composition comprising from 75 to 95 percent by weight polyalphaolefin base oil; and from 7.5 to 25 percent by weight oil soluble polyalkylene glycol (osp) additive, wherein the polyalkylene glycol has a viscosity at 40° c. From 15 cst to 50 cst and comprises units derived from propylene oxide and units derived from butylene oxide; wherein the lubricant composition exhibits a four ball ep weld load result of at least 160 kg and an air release value at 75° c.
Dow Global Technologies Llc
Biomimetic boundary lubricants for articular cartilage
This invention relates to methods of lubrication for biological tissue, especially joint and cartilage surfaces, and to methods of treating osteoarthritis using high molecular weight, hydrophilic polymer brushes, which mimic the structure and activity of lubricin. These synthetic lubricin analog polymer brushes (termed herein graft brush polymers), include poly(acrylic acid) back-bones grafted with polyethylene glycol..
Alternative fuel and fuel additive compositions
Alternative gasoline, diesel fuel, marine diesel fuel, jet fuel, and flexible fuel compositions are disclosed. The compositions include an alcohol and/or a glycerol ether or mixture of glycerol ethers, which can be derived from renewable resources.
Cps Biofuels, Inc.
Ink formulations for improving printhead lifetime
(ii) sulfolane; (iii) a glycol compound selected from the group consisting of: ethylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol and pentaethylene glycol; and (iv) water.. .
Thermoplastically processable transparent blends of thermoplastic polyurethane and poly(meth)acrylates
The present invention relates to compositions comprising at least one thermoplastic polyurethane and at least one poly(meth)acrylate, where the at least one thermoplastic polyurethane is a polyurethane based on hexamethylene 1,6-diisocyanate (hdi), on at least one diol, and on at least one chain extender, selected from the group consisting of ethylene 1,2-glycol, 1,2-propanediol, 1,3-propanediol, 1,4-butanediol, 2,3-butanediol, 1,5-pentanediol, 1,6-hexanediol, diethylene glycol, dipropylene glycol, 1,4-cyclohexanediol, 1,4-dimethanolcyclohexane, and neopentyl glycol. The present invention further relates to moldings comprising the compositions of the invention, and also to the use of the compositions of the invention for producing a foil and for coating a molding..
Acylated glucagon analogues
The present invention relates to novel peptide compounds which have an improved physical stability in solution and improved solubility at neutral ph, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity..
Novo Nordisk A/s
Glp-1 analogue, its preparation methods and use thereof
Wherein x10 is glycine or cysteine, x15 is aspartic acid or cysteine, x22 is glycine or cysteine, x30 is alanine or cysteine, x33 is valine or cysteine, and at least one of x10, x15, x22, x30 and x33 is cysteine, x1 and x2 respectively is glycine, alanine or valine, n1=1-30, n2=1-30. The general formula a contains two cysteines to form disulfide bonds.
The invention is directed to the use of at least one peptide of formula: x-(xaa1)n-pro*-(xaa2)m-y (i) with: —n=0, or 2; —m=0 or land if m=0 then n≠0 —xaa is: —an hydrophobic aminoacid selected from alanine (ala, a), valine (val, v), methionine (met, m), leucine (leu, l), isoleucine (ile, i), phenylalanine (phe, f), proline (pro, p) and analogues and derivatives thereof; —a polar aminoacid selected from serine (ser, s), threonine (thr, t), tyrosine (tyr, y), asparagine (asn, n), glutamine (gln, q) and analogues and derivatives thereof; or —glycine (gly, g); when n=2 the two aminoacids xaa1 can be the same or different; —xaa2 is: —an hydrophobic aminoacid selected from alanine (ala, a), valine (val, v), methionine (met, m), leucine (leu, l), isoleucine (ile, i), phenylalanine (phe, f), proline (pro, p) and analogues and derivatives thereof; —a basic aminoacid selected from arginine (arg, r), lysine (lys, k) and histidine (his, h) and analogues and derivatives thereof; —glycine (gly, g) or serine (ser, s); —at the n terminal end of the peptide, x is selected from h, —co—r1 and —so2—r1; —at the c terminal end of the peptide, y is selected from oh, or1, nh2, nhr1 or nr1r2, —r1 and r2 being independently from each other, selected from an alkyle, aryle, aralkyle, alkylaryl, alkoxy and aryloxy group, that can be linear, branched, cyclic, poly-cyclic, non-saturated, hydroxylated, carbonylated, phosphorylated and/or sulphured, with the possibility to have in said group skeleton a o, s and/or n heteroatom; —pro* corresponding to a proline, an analogue or derivative thereof; excluding the peptides where x=h and y=oh, for a non therapeutical cosmetic pro-pigmenting treatment of skin. The invention also encompasses new tripeptides of formula (i) suitable for a non therapeutical cosmetic treatment of skin..
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
Wherein the variables are as defined in the claims or the description, which are useful for inhibiting glycogen synthase kinase 3 (gsk-3), compositions containing the compounds, their use for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a compound that modulates, preferably inhibits, the activity of glycogen synthase kinase 3β, and methods of treatment of medical disorders susceptible to treatment with a compound that modulates glycogen synthase kinase 3β activity using the compounds.. .
Solid forms of nilotinib hydrochloride
Disclosed are solid forms of nilotinib hydrochloride and methods of preparation of various crystalline solvates of nilotinib hcl including benzyl alcohol, acetic acid, propylene glycol, and isopropanol. Nilotinib hcl is a tyrosine kinase inhibitor used for the treatment of drug resistant chronic myelogenous leukemia (cml)..
Apotex Technologies Inc.
Optimised coding sequence and promoter
An optimized coding sequence of human blood clotting factor eight (viii) and a promoter may be used in vectors, such as raav, for introduction of factor viii, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocyte biology, lysosomal storage, urea cycle disorders, and lipid storage diseases.
St. Jude Children's Research Hospital
Thermo-sensitive, mucoadhesive or dermoadhesive, and penetration-enhancing formulations for topical delivery of therapeutics
The present invention provides thermo-sensitive, mucoadhesive biopolymer formulations that enhance the penetration of therapeutics across the skin or mucosal surfaces. In a preferred embodiment, the biopolymer formulation comprises co-polymer of poloxamer 188 and propylene glycol, laurocapram and, optionally, one or more therapeutic agents.
University Of Florida Research Foundation, Inc.
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate.
Globo h and related anti-cancer vaccines with novel glycolipid adjuvants
An immunogenic composition containing a glycan conjugate including a carrier protein, and a glycan including globo h, an immunogenic fragment thereof, or stage-specific embryonic antigen-4 (ssea-4), wherein the glycan is conjugated with the carrier protein through a linker.. .
Gene therapy for glycogen storage diseases
The present invention relates to a transcription factor eb (tfeb) protein, ortholog, recombinant or synthetic or bio technological functional derivative thereof, allelic variant thereof and fragments thereof; a chimeric molecule comprising the tfeb protein, ortholog, recombinant or synthetic or biotechnological functional derivative thereof, allelic variant thereof and fragments thereof; a polynucleotide coding for said protein or ortholog, recombinant or synthetic or biotechnological functional derivative thereof, allelic variant thereof and fragments thereof; a vector comprising said polynucleotide; a host cell genetically engineered expressing said polypeptide or a pharmaceutical composition for use in the treatment or/and prevention of a glycogen storage disease. Preferably of pompe or danon disease..
Pharmaceutical composition for increasing content and availability of cyclic adenosine monophosphate in a body and preparation thereof
The present invention discloses a pharmaceutical composition to rapidly increase a content and an availability of a cyclic adenosine monophosphate (camp) in a body, including: ginsenosides rg1, rb1 and re, a glycyrrhiza related acid being one selected from a group consisting of a glycyrrhizic acid, a glycyrrhetinic acid and a combination thereof, and a jujuba cyclic adenosine monophosphate (jujuba camp).. .
Antiviral supplement formulations
The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure.
Topical compositions and methods of treatment of anorectal disorders
A topical anorectal composition includes trimethylsiloxysilicate; at least one surfactant selected from the group consisting of sodium lauryl sulfate, alkyl- and alkoxy-dimethicone copolyol, polysorbate and a combination thereof; a non-polar volatile siloxane solvent; at least 15% (w/w) water, and a pharmaceutical agent selected from the group consisting of pramoxine, phenylephrine, hydrocortisone, salicylic acid, nitroglycerine, sildenafil, or their salts and combinations thereof, wherein the composition is sufficiently designed to dry within 60 seconds after application to the anorectal mucosa to form a dried composition, and wherein the dried composition forms: a flexible film, wherein the flexible film closely follows irregularities of the body surface as well as movement of the body surface, and (ii) a durable film, wherein the durable film does not crack or flake off and remains intact for more than 12 hours giving release of the pharmaceutical agent for an extended period of time.. .
Peritech Pharma Ltd.
Inhibitors of protein kinases
Wherein r1, r2, r3, ra, a, b and x are as defined herein are inhibitors of protein kinases in particular members of the cyclin-dependent kinase family and/or the glycogen synthase kinase 3 family and are useful in preventing and/or treating any type of pain, inflammatory disorders, cancer, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases, metabolic disorders, renal diseases, neurologic and neuropsychiatric diseases and neurodegenerative diseases.. .
Novel triglyceride reducing agent
The present invention relates to hypotriglyceridemic agent containing hmg-coa reductase inhibitor and camp protease inhibitor.. .
Kowa Company, Ltd.
Compounds for reducing glucocorticoids, and methods of treatment thereof
A method for reducing glucocorticoids in an animal in need thereof comprising the use of compounds of the formula (i), wherein the definitions for r′, r1-r11 and n are as disclosed in the description. The compounds of formula (i) are for the treatment or prevention of a glucocorticoid-related disorder for maintaining bone density, maintaining and improving the immune system, treating cushing's syndrome, treating obesity, improving reproduction efficiency, treating metabolic disorder, treating hypertension, treating hyperglycemia, treating insulin resistance, treating type 2 diabetes, and/or aiding in cancer and immune therapies.
University Of Ottawa
Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
The present invention provides methods of limiting cell death resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a hypoxic-ischemia insult. The omega-3 lipid-based emulsion preferably comprises at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglycerides and/or diglycerides, and wherein fatty acids of the omega-3 trigylceride and/or diglycerides comprise at least 40% epa and/or dha.
The Trustees Of Columbia University In The City Of New York
Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs
The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-β-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-apb, and preferably consists of meclofenamic acid.
Bio Modeling Systems Ou Bmsystems
Composition of vegetable soft capsule having excellent elasticity and adhesive property, provided in form of thin film, and having improved productivity and disintegration, and preparing the same
Disclosed are a composition of a vegetable soft capsule having excellent elasticity and an excellent adhesive property, provided in the form of a thin film, and having improved productivity and disintegration, and a method of preparing the same. Based on 35.3 weight part of the starch and the carrageenan, 7 weight part of the starch and 3 weight part of carrageenan are provided.
Chang Sung Softgel System Ltd
Systems for treating pulmonary infections
Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids.
Essential oil and herbal extract mist composition and delivery
A liquid composition that includes essential oils, herbal extracts or a combination thereof is provided. The liquid composition further includes a base carrier.
Oromucosal apomorphine compositions
An oromucosal solution comprising about 1-8% (w/v) apomorphine or a pharmaceutical acceptable salt thereof solubilised in a non-aqueous carrier containing at least about 50% (v/v) of propylene glycol. A small volume (25-250 μl) of said solution containing about 1-12 mg apomorphine may be administered upon demand to treat motor fluctuations during off periods in patients suffering from parkinson's disease.
Inhalation-type pharmaceutical composition for the treatment of heart disease and preparation method thereof
The present invention provides an inhalation-type pharmaceutical composition for heart disease and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen.
(c8) glycyrrhizic acid or plant extracts comprising it.. .
Manufacturing brown seaweed extracts containing alginate
A method of preparing a brown seaweed extract containing alginate is disclosed. The method includes washing brown seaweed containing alginate to remove impurities, mixing alginate contained in the brown seaweed with glycerin by precipitating and soaking at a temperature of 70 to 80° c.
Surfactant composition for use in glyphosate-containing herbicide formulations, glyphosate-containing herbicide formulation, and use of the glyphosate-containing herbicide formulation
Wherein r1 is hydrogen or c1-18 hydrocarbyl; each x is independently an ether, thioether, sulfoxide, ester, thioester or amide bond; each r2 is independently a c3-6 chain; m is a number from 0 to 8 such that the number of carbon atoms in r1—(xr2)m is from 8 to 24; r3 and r4 are independently hydrogen or c1-4 chains; r5 is hydrogen or methyl. The surfactant composition is used to increase the agronomic efficacy of herbicide formulations containing a high concentration of glyphosate salts.
Method for preparation of an aqueous glyphosate concentrate
A method for preparing an aqueous mixture of glyphosate salts to improve the handling of the mixture, the method comprising forming a homogeneous mixture of at least two bases comprising at least one alkali metal hydroxide, and at least one further base selected from alkali metal hydroxides and nitrogen bases and reacting the mixture of the at least two bases with glyphosate acid in an aqueous reaction medium to provide an aqueous mixture of glyphosate salts wherein the concentration of glyphosate (based on glyphosate acid equivalent) is at least 200 gae/l.. .
Nufarm Australia Limited
Electrochemical plating methods
An electrochemical process for applying a conductive film onto a substrate having a seed layer includes placing the substrate into contact with an electrochemical plating bath containing cobalt or nickel, with the plating bath having ph of 4.0 to 9.0. Electric current is conducted through the bath to the substrate.
Applied Materials, Inc.
Glyphosate tolerant alfalfa events and methods for detection thereof
The present invention provides for alfalfa events j-101 and j-163 and dna molecules unique to these events. The invention also provides methods for detecting the presence of these dna molecules in a plant sample..
Monsanto Technology Llc
Recombinant microorganism with ability to produce glycerol, 3-hp, or acrylic acid and producing glycerol, 3-hp, or acrylic acid by using the same
A recombinant microorganism having the ability to produce glycerol 3-hp, or acrylic acid, in which glycerol is produced from dihydroxyacetone phosphate (dhap) via dihydroxyacetone (dha) in a biosynthetic pathway, and a method of producing glycerol, 3-hydroxypropioninc acid (3-hp), or acrylic acid by using the recombinant microorganism.. .
Samsung Electronics Co., Ltd.
Pichia pastoris strains for producing predominantly homogeneous glycan structure
Disclosed herein are novel pichia pastoris strains for expression of exogenous proteins with substantially homogeneous n-glycans. The strains are genetically engineered to include a mutant och1 allele which is transcribed into an mrna coding for a mutant och1 gene product (i.e., α-1,6-mannosyltransferase, or “och1 protein”).
Research Corporation Technologies, Inc.
Production of commercial biodiesel from genetically modified microorganisms
The invention provides a fermentation and recovery process for the production of biodiesel of commercial grade quality according to commercial and environmental standards (e.g., astm anp, or epa trace elements and emissions standards), by fermentation of carbohydrates using a genetically modified microorganism. The process provides a direct route for the production of fatty esters, without the need for producing oils which are later chemically transesterified with the concomitant production of large quantities of glycerin and other undesirable side-products..
Reg Life Sciences, Llc
A concentrated aqueous composition may be prepared by from a formulation including: a. From 10 to 30 % by weight (% wt) of a depolymerized carboxymethyl cellulose having a weight average molecular weight of from about 10,000 to about 80,000 dalton (da); b.
Post-treatment solution for digital inkjet printing
A post-treatment solution for digital inkjet printing includes polymer particulates having a minimum film-forming temperature that is at least 50° c., a film-forming agent, and a liquid carrier. The film-forming agent is selected from the group consisting of citrate compounds, sebacate compounds, ethoxy alcohols, glycol oligomers, glycol polymers, glycol ether, glycerol acetals, and cyclic amides.
Hewlett-packard Development Company, L.p.
Monoclonal antibodies with enhanced adcc function
The invention concerns a method for obtaining and selecting monoclonal antibodies by an addc-type test, said antibodies capable of activating type iii fcy receptors and having a particular glycan structure. The inventive anti-d antibodies can be used for preventing rhesus isoimmunisation in rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9itp).
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
Disclosed herein among other mn/ca ix-related inventions are new mn/ca ix-specific antibodies generated from mn/ca ix-deficient mice, preferably monoclonal antibodies and immunoreactive fragments and engineered variants thereof. Subsets of the new antibodies are to either the proteoglycan-like (pg) domain or to the carbonic anhydrase (ca) domain of mn/ca ix, and methods are provided by which antibodies can be prepared to the other mn/ca ix domains.
Virus-like particles, methods of preparation, and immunogenic compositions
Briefly described, virus-like particles, methods of preparing virus-like particles, immunogenic compositions that include virus-like particles, and methods of eliciting an immune response using immunogenic compositions that include virus-like particles are described herein. A virus-like particle (vlp) can include a viral core protein that can self assemble into the vlp core and at least one viral surface envelope glycoprotein expressed on the surface of the vlp.
Method for preparing monoacetyglycerols and esters thereof
Disclosed are a method for preparing 1-acyl-3-acetylglycerol in high purity and high yield without a purification process using a column chromatography, and a method for preparing 1,2-diacyl-3-acetylglycerol in high purity and high yield using the same as a key intermediate. The method includes the steps of: forming a reaction mixture including 1-acyl-3-acetyl glycerol of the formula 1 in the specification by reacting 1-acylglycerol of the formula 2 in the specification and an acetylating agent; and separating the racemic or optically active 1-acyl-3-acetylglycerol by crystallizing the reaction mixture in a saturated hydrocarbon solvent having 5 to 7 carbon atoms..
Enzychem Lifesciences Corporation
Systems and methods of refining natural oil feedstocks and derivatives thereof
Systems and methods are disclosed for refining natural oil feedstocks. In some embodiments, the methods comprise transesterifying glycerides in a natural oil feedstock to provide a transesterified product comprising monounsaturated fatty acid esters and polyunsaturated fatty acid esters.
Elevance Renewable Sciences, Inc.
Paraffinic jet and diesel fuels and base oils from vegetable oils via a combination of hydrotreating, paraffin disproportionation and hydroisomerization
The present invention relates to a new process which comprises the steps of hydrotreating, paraffin disproportionation and hydroisomerization to convert biological hydrocarbonaceous oxygenated oils comprising triglycerides into biologically-derived paraffinic jet/diesel fuels, solvents and base oils. A combination of conventional hydrogenation/dehydrogenation catalysts, such as pt/al2o3, and conventional olefin metathesis catalysts, such as wo3/sio2, or inexpensive variations thereof, is generally employed in the paraffin disproportionation step..
Chevron U.s.a. Inc.
Novel lipids and compositions for the delivery of therapeutics
Wherein r1 and r2 are each independently for each occurrence optionally substituted c10-c30 alkyl, optionally substituted c10-c30 alkenyl, optionally substituted c10-c30 alkynyl, optionally substituted c10-c30 acyl, or -linker-ligand; r3 is h, optionally substituted c1-c10 alkyl, optionally substituted c2-c10 alkenyl, optionally substituted c2-c10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ω-aminoalkyls, ω-(substituted)aminoalkyls, ω-phosphoalkyls, ω-thiophosphoalkyls, optionally substituted polyethylene glycol (peg, mw 100-40k), optionally substituted mpeg (mw 120-40k), heteroaryl, heterocycle, or linker-ligand; e is o, s, n(q), c(o), n(q)c(o), c(o)n(q), (q)n(co)o, o(co)n(q), s(o), ns(o)2n(q), s(o)2, n(q)s(o)2, ss, o═n, aryl, heteroaryl, cyclic or heterocycle; and, q is h, alkyl, ω-aminoalkyl, ω-(substituted)aminoalky, ω-phosphoalkyl or ω-thiophosphoalkyl.. .
Transmucosal delivery of tocotrienol
The present invention relates to pharmaceutical compositions formulated for transmucosal delivery, and in particular sublingual delivery, comprising at least one tocotrienol or derivative thereof together with one or more pharmaceutically acceptable excipients. The present further relates to the use of said compositions for treating or preventing post exercise muscle soreness, delayed onset muscle soreness, cardiac fibrosis, hypertension, inflammation, stroke, cancer, elevated cholesterol and/or triglycerides, baldness, hypertrophy, conditions resulting from radiation exposure, stabilizing and/or controlling blood glucose levels, and improving exercise endurance and capacity..
Gordagen Pharmaceuticals Pty Ltd
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.. .
Amarin Pharmaceuticals Ireland Limited
Stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone
An aqueous pharmaceutical solution composition comprising between about 20 mg/ml to about 100 mg/ml of a radioprotective α,β-unsaturated aryl sulfone, a cosolvent comprising polyethylene glycol (peg), polypropylene glycol, polyglycerol, dma, propylene glycol, glycerol, ethanol, sorbitol, isopropyl alcohol, or a combination thereof in an amount between about 25% and about 90% w/v, and a water soluble vitamin e derivative, wherein the composition has a ph within the range of about 7.0 to about 9.5.. .
Onconova Therapeutics, Inc
Formulation for retinoid-containing soft gelatin capsules
A new pharmaceutical formulation for retinoid-containing soft gelatin capsules is disclosed. The new formulation comprises a soft gelatin capsule filled with a fill mass comprising a retinoid as an active ingredient, a natural vegetable oil, a partially hydrogenated natural vegetable oil and medium chain triglycerides.
Glaxo Group Limited
Disclosed is an oil-in-water anionic emulsion for eyelashes, and methods for its use, comprising a continuous phase comprising 35 to 55% by weight of water based on the total weight of the emulsion, a discontinuous phase comprising 15 to 25% by weight of a combination of waxes, wherein the combination of waxes comprises paraffin wax, carnauba wax, beeswax, and candelilla wax based on the total weight of the emulsion, and 5 to 15% by weight of the emulsion of an anionic surfactant system comprising stearic acid, palmitic acid, myristic acid, polyethylene glycol-40 (peg-40) stearate, and stearyl stearate, wherein the oil-in-water anionic emulsion is capable of thickening the appearance of eyelashes.. .
Mary Kay Inc.
Microcapsule comprising glycoprotein derived from plants
The present invention relates to a microcapsule containing a glycoprotein derived from plants. Also, the present invention provides a microcapsule having oxidation ability and which is easy to prepare.
Method and detecting false hypoglycemic conditions
Embodiments of the present disclosure include detecting a concurrent occurrence of a decrease in monitored analyte level and a corresponding decrease in monitored on-skin temperature, confirming a presence of an impending hypoglycemic condition, and asserting a notification corresponding to the confirmed impending hypoglycemic condition. Devices, methods, systems and kits incorporating the same are also provided..
Abbott Diabetes Care Inc.
Nutritional beverage product
A beverage product, and composition therefore, for providing relief from hangover symptoms by replenishment or preventative hydration and supplementation of nutrients lost as a result of alcohol consumption comprising a composition causing the beverage to be hypo-osmolar and comprise a low glycemic index. Also, a method of relieving hangover symptoms by replenishment or preventative hydration and supplementation of nutrients lost as a result of alcohol consumption comprising providing to a mammal a beverage including a composition causing the beverage to be hypo-osmolar and comprise a low glycemic index..
Fortis Beverages, Llc
Methods for improving plant growth
Methods of improving the growth of a plant by applying a plant growth effective amount of a plant growth composition that includes a hydrated aluminum-magnesium silicate and at least one dispersant selected from the group consisting of a sucrose ester, a lignosulfonate, an alkylpolyglycoside, a naphthalenesulfonic acid formaldehyde condensate and a phosphate ester to plant propagation material in the absence of insect pest pressure.. .
Liquid agrochemical compositions comprising a polymeric thickener and an alcohol-containing solvent system, and liquid herbicidal compositions having an alcohol-containing solvent system
The invention provides a liquid agrochemical composition, preferably in the form of an emulsifiable concentrate (ec), comprising a mixture of: one or more agrochemically active ingredients (in particular comprising one or more herbicides); a c1-c6 alkyl methacrylate polymer (preferably an isobutyl methacrylate polymer); and a solvent system comprising: (c1) an alcohol solvent comprising hexylene glycol (2-methyl-2,4-pentanediol), benzyl alcohol, diacetone alcohol (2-methyl-4-oxo-pentane-2-ol), isobutanol, n-pentanol, n-hexanol, n-heptanol, n-octanol, 2-ethyl-hexanol, cyclohexanol, dipropylene glycol, diethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, ethylene glycol, or a mixture of two or more of these alcohols (preferably hexylene glycol); and (c2) a heavy aromatic hydrocarbon solvent. The c1-c6 alkyl methacrylate polymer generally acts as a thickener which is suitable for the defined solvent system, and which is for increasing the viscosity of the composition.
Syngenta Participations Ag
Conductive thin film comprising silicon-carbon composite as printable thermistors
A method of fabricating a temperature sensing device based on printed silicon-carbon nanocomposite film is disclosed. This method includes high-crystal-quality si nanoparticles (nps) homogeneously mixed with carbon nps and si—c nanocomposites printed as negative temperature coefficient (ntc) thermistor.
Nano And Advanced Materials Institute Limited
Electrically conductive paste composition and forming an electrical circuit on a polymer substrate
An electrically conductive paste composition for forming an electrical circuit comprising: (a) a flake-shaped silver powder, wherein the mean particle size (d50) of the silver powder is 2.0 to 8.0 μm; and (b) a polyvinyl acetal resin, wherein the viscosity of a 10 wt % solution of the polyvinyl acetal resin in di-propylene glycol methyl ether is no less than 1 pa·s as measured with a brookfield viscometer (10 rpm, at 25° c.); and wherein the weight ratio of (a) to (b) is in the range from 87/13 to 95/5.. .
E I Du Pont De Nemours And Company
Liquid mixture used to test and validate test devices for inspecting objects or persons
A liquid mixture is used to test and validate test devices for inspecting objects or persons, said mixture containing glycerol and sodium hydroxide, in a weight ratio of glycerol to solid hydroxide between 6.5 and 3.8, and containing water.. .
Smiths Heimann Gmbh
Method and kit for distinguishing between prostate carcinoma and benign prostatic hyperplasia
An object of the present invention is to provide a method for distinguishing between prostate carcinoma and benign prostatic hyperplasia with high sensitivity and good reproducibility using a small amount of an analyte sample. The method for distinguishing between prostate carcinoma and benign prostatic hyperplasia according to the present invention as a solution means thereof comprises: bringing an analyte sample containing a prostate-specific antigen (psa) into contact with a carrier having an anti-free psa antibody immobilized thereon, thereby binding free psa to the anti-free psa antibody immobilized on the carrier; thereafter bringing the carrier in which the free psa is bound to the immobilized anti-free psa antibody into contact with a monoclonal antibody capable of specifically recognizing a glycan in which a terminal sialic acid residue is bound to galactose through an α(2,3) bond, thereby binding the monoclonal antibody capable of specifically recognizing a glycan in which a terminal sialic acid residue is bound to galactose through an α(2,3) bond to the free psa bound to the anti-free psa antibody immobilized on the carrier; measuring the amount of the free psa having an n-type glycan in which a terminal sialic acid residue is bound to galactose through an α(2,3) bond; comparing the measured amount thus obtained with a preset cutoff value for prostate carcinoma and benign prostatic hyperplasia, thereby determining that when the measured amount is larger than the cutoff value, prostate carcinoma is developed or the probability of developing prostate carcinoma is high, and when the measured amount is smaller than the cutoff value, benign prostatic hyperplasia is developed or the probability of developing benign prostatic hyperplasia is high..
Shizuoka Prefectural University Corporation
Assays for detection of glycosaminoglycans
Disclosed herein are novel methods, assays and kits useful for the diagnosis and monitoring of subjects with mucopolysaccharidoses (mps), the methods, assays and kits are particularly useful for detecting the presence of one or more glycosaminoglycans which correlate to mps and its severity in a variety of biological samples.. .
Shire Human Genetic Therapies, Inc.
Popular terms: [SEARCH]
Gly topics: Door Assembly, Swimming Goggles, Transverse, Alkoxylate, Fluoropolymer, Air Cleaning, Rotor Shaft, Aspect Ratio, Disconnect, Synchronization, Remote Control, Ethylene Glycol, Surfactant, Combustion, Steviol Glycosides
Follow us on Twitter
This listing is a sample listing of patent applications related to Gly for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Gly with additional patents listed. Browse our RSS directory or Search for other possible listings.